Skip to content
NewsBlazeIN – Lifestyle
Author:
Candel Therapeutics
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 26, 2026
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
←
Previous Page
1
2
3